for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DelMar Pharmaceuticals Inc

DMPI.OQ

Latest Trade

0.51USD

Change

0.02(+3.22%)

Volume

16,556

Today's Range

0.49

 - 

0.54

52 Week Range

0.38

 - 

5.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Delmar Pharma Enrolls Final Patient In Phase 2 Clinical Trial Of Val-083 For First-Line Treatment Of Brain Tumors

Feb 19 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS [NASDAQ:DMPI] ENROLLS FINAL PATIENT IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR FIRST-LINE TREATMENT OF BRAIN TUMORS.DELMAR PHARMACEUTICALS INC - ANTICIPATES EARLIER THAN EXPECTED PRELIMINARY DATA READOUT IN AUGUST 2020.DELMAR PHARMACEUTICALS INC - HAS BEEN MONITORING CORONAVIRUS SITUATION IN CHINA.DELMAR PHARMACEUTICALS - CORONAVIRUS OUTBREAK WILL NOT HAVE SIGNIFICANT IMPACT ON PATIENT TREATMENT TIMELINE.

Delmar Pharmaceuticals Q2 Loss Per Share $0.15

Feb 13 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES.Q2 LOSS PER SHARE $0.15.

Delmar Pharma Says Offering 7.8 Mln Shares Of Common Stock Issuable Upon Exercise Of Previously Issued Warrants

Nov 21 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS INC - OFFERING 7.8 MILLION SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF PREVIOUSLY ISSUED WARRANTS -SEC FILING.

Delmar Pharmaceuticals Q1 Loss Per Share $0.21

Nov 14 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES.Q1 LOSS PER SHARE $0.21.DELMAR PHARMACEUTICALS - AT SEPT 30, CO HAD CASH AND CASH EQUIVALENTS ON HAND OF ABOUT $8.1 MILLION.

DelMar Says During Audit For Year-Ended June 30, 2019, Material Weakness In Operating Effectiveness Of Internal Controls Over Financial Reporting Was Identified

Oct 1 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR- DURING AUDIT FOR YEAR-ENDED JUNE 30, 2019, MATERIAL WEAKNESS IN OPERATING EFFECTIVENESS OF INTERNAL CONTROLS OVER FINANCIAL REPORTING WAS IDENTIFIED.DELMAR - WEAKNESS RELATED TO INADEQUATE SEGREGATION OF DUTIES OVER AUTHORIZATION, REVIEW & RECORDING OF TRANSACTIONS, AS WELL AS FINANCIAL REPORTING.DELMAR PHARMACEUTICALS INC - ON SEPT. 30, E&Y RESIGNED AS CO'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM..

DelMar Pharmaceuticals Files For Offering 6 Mln Shares Of Common Stock

Aug 1 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS INC FILES FOR OFFERING 6 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING.

DelMar Pharmaceuticals Enrolls First Patient In The Recently-Approved Adjuvant Setting Arm Of Phase 2 Study Of VAL-083

July 24 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ENROLLS FIRST PATIENT IN THE RECENTLY-APPROVED ADJUVANT SETTING ARM OF PHASE 2 STUDY OF VAL-083 FOR THE TREATMENT OF MGMT-UNMETHYLATED GLIOBLASTOMA MULTIFORME.DELMAR PHARMACEUTICALS INC - DELMAR IS ACTIVELY ENROLLING PATIENTS FOR BOTH TRIAL ARMS OF CLINICAL STUDY AT MDACC..DELMAR PHARMACEUTICALS INC - CONDUCTING A PHASE 2 CLINICAL STUDY OF VAL-083 AS FIRST LINE TREATMENT FOR GBM IN COMBINATION WITH RADIOTHERAPY IN CHINA.

Delmar Pharmaceuticals Files Prospectus Relates To Resale By Selling Stockholders Of Up To 760,500 Shares Of Co's Common Stock - SEC Filing

June 25 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS FILES PROSPECTUS RELATES TO RESALE BY SELLING STOCKHOLDERS OF UP TO 760,500 SHARES OF CO'S COMMON STOCK - SEC FILING.

Delmar Provides Clinical Update On Val-083 From Ongoing 1st & 2nd-Line Trials In Patients With MGMT-unmethylated Glioblastoma

June 3 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PROVIDES CLINICAL UPDATE ON VAL-083 FROM ONGOING FIRST- AND SECOND-LINE TRIALS IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA AT A KEY OPINION LEADER FORUM DURING THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING.DELMAR PHARMACEUTICALS INC - FOURTEEN OF EIGHTEEN PATIENTS WERE STILL ALIVE AT DATA CUT-OFF DATE.DELMAR PHARMACEUTICALS INC - AS OF MAY 17, 2019, EIGHTEEN PATIENTS HAVE BEEN ENROLLED IN TRIAL.DELMAR PHARMACEUTICALS INC - TRIAL IS DESIGNED TO ENROLL UP TO 30 PATIENTS.DELMAR PHARMACEUTICALS INC - TWO PATIENTS HAVE NOT BEEN ON STUDY LONG ENOUGH TO REACH FIRST ASSESSMENT, AND 1 PATIENT DIED BEFORE FIRST ASSESSMENT.DELMAR - ALSO UPDATED ON ONGOING SECOND-LINE PHASE 2 CLINICAL STUDY OF VAL-083 IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GBM.

Delmar Pharmaceuticals Announces 1-For-10 Reverse Stock Split

May 7 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.DELMAR PHARMACEUTICALS - REVERSE STOCK SPLIT EFFECTIVE FOR TRADING PURPOSES AS OF COMMENCEMENT OF TRADING ON MAY 8, 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up